Semaglutide vs Compounded Tirzepatide
A side-by-side research comparison of Semaglutide and Compounded Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Semaglutide | Compounded Tirzepatide |
|---|---|---|
| Full name | Semaglutide (GLP-1 Receptor Agonist) | Compounded Tirzepatide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Compounded medication |
| Mechanism | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. | Dual agonist of both GLP-1 and GIP receptors. GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances fat metabolism, improves insulin sensitivity, and may protect against muscle loss. |
| Molecular weight | 4,114 Da | 4813.45 Da |
| Half-life | 7 days (168 hours) | ~5 days |
| Bioavailability | High (SubQ ~89%), Moderate (oral ~1% with SNAC) | ~80% subcutaneous |
| Typical dose | 0.25 mg → titrate up to 2.4 mg | 2.5-15 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Compounded Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Dual incretin pathway activation
- Better muscle preservation
- Improved A1c
- Cardiovascular protection
- Reduced insulin resistance
Related comparisons
Research and educational reference only. Not medical advice.